Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
about
Early versus delayed erythropoietin for the anaemia of end-stage kidney diseaseErythropoiesis-stimulating agents for anaemia in chronic kidney disease: Are they all the same?Early versus delayed erythropoietin for the anaemia of end-stage kidney diseasePhysiology and pharmacology of erythropoietinEfficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review.Cost-effectiveness of continuous erythropoietin receptor activator in anemia.Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM studyEpoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.High dose EPO--friend or foe in the newborn?Anemia in chronic kidney disease.Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
P2860
Q24187089-85FC8E28-24B4-4B33-AF27-EB5943B26D11Q24187090-F4EF4DC0-1897-4156-943E-CD79B8336022Q24194838-0DD02FE7-475E-407A-B5B9-B7E7CFA4CBE5Q26866945-4ADADF46-6C2F-4961-B49A-E7B3C54EEEEEQ30911529-DD84A5C3-1CF9-41D1-B96F-9843D45BF862Q33874659-AC18DD26-1EAD-4E8A-A852-9C35C2430BF5Q34352446-A8C064F9-2EBB-46FD-A7D5-1B203B8E9AFCQ34577650-48E53E18-6115-4899-8EDC-1FC39FB58E32Q35162053-8E16C97B-3394-412B-9EB6-4EB40CD2DF25Q37501907-5A5EE4A2-F58F-437F-B614-5A91940FA076Q38556990-57EF6154-AF83-44A1-BBDF-E9CA153EF1A4Q38634832-248C64E3-3098-4FAD-B0FB-3A7EB54F8167Q51726577-E0A55167-0175-49C7-AFC6-2B1B4897F91EQ53354670-5E83B031-1B3A-4D8E-B144-9D3ECB36ECC9Q55274440-BB2A99C8-58F2-468E-A948-1BAE13A59A54
P2860
Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
type
label
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
prefLabel
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
P2860
P1433
P1476
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
P2093
Walter H Hörl
P2860
P2888
P304
P356
10.1007/S40265-012-0002-2
P577
2013-02-01T00:00:00Z
P6179
1032276411